In-depth studies showed that pyrimethamine treatment of ovarian cancer cells for 24 h did not induce caspase-3 cleavage, and cleaved caspase-3 could only be measured after 48 or 72 h of pyrimethamine administration. The gene discussed is CASP3; the disease is ovarian carcinoma.